Funding success for digital diabetes treatment

Funding success for digital diabetes treatment

An app which gives people with diabetes personalised treatment, has secured an investment deal to to help people suffering with the condition.

Gendius, the company behind the app, has announced completion of its deal with Catapult Ventures which will result in the creation of jobs and the commercialisation of their Intellin App.

The company, based at BioHub Alderley Park, Cheshire, has recently attracted grant funding into the region from both Innovate UK and SBRI to complete studies using the Intellin platform.

Dr Hakim Yadi OBE, CEO of Northern Health Science Alliance said: “It is great to see health innovation being funded and commercialised in the North of England.

“Gendius has been working within the Northern health economy and has now attracted local Venture Capital to take their product forward. What we need to see now is greater investment like this in the North.

“The whole Northern region is innovation rich and capital poor, to deliver a Northern Powerhouse we need a new flow of capital to support innovations like these succeed and make a difference to patients’ lives.”

Gendius was founded by Chris Genders and Rory Cameron with a view to making living with diabetes easier. The company has developed Intellin - an App platform that uses an individual’s clinical history to predict those areas most likely of developing complications from their diabetes i.e. their individual high-risk areas.

The platform then focusses the individual on clinically validated tasks and measures to slow their progression in these areas. The Intellin platform is currently undergoing clinical trials and has won significant grant funding from both Innovate UK and the SBRI.

Chris Spencer, a digital health advisor with Catapult Ventures, will join the board of Gendius as non-executive Chairman in early 2018. Until April 2017 Chris was CEO of EMIS Group Plc where he had held senior roles since 1999.

Chris Genders, CEO Gendius, said “I’m extremely pleased to welcome the GM&C Life Sciences Fund as an investor in Gendius and welcome Chris as Chair elect. Chris’s wide-ranging experience in the leadership and management of healthcare technology businesses will be extremely valuable to Gendius as we seek to further enhance and commercialize our digital applications for diabetes and grow Gendius as a leader in this area.”

Dr Vijay Barathan, Life Science Partner with Catapult Ventures said “We are excited by this opportunity and fully support the approach Gendius is taking to develop a scalable and sustainable digital health business.”

Chris Spencer, said “I am looking forward to working with Chris, Rory, and the team to fulfil the potential of their application to improve clinical outcomes in this area of high patient need and payer/provider cost.”